Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study

Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study

Combination therapy with inhibitors of cytotoxic T lymphocyte-associated protein (CTLA)4 and programmed death (PD)-1 has demonstrated efficacy in cancer patients. However, there is little information on CTLA4 and PD-1 expression levels and their clinical significance across diverse cancers. In this...

Full description

Bibliographic Details
Main Authors: Jian-Nan Liu, Xiang-Shuo Kong, Tao Huang, Rui Wang, Wang Li, Qi-Feng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Immunology
Subjects:
pan-cancer
PD-1
CTLA4
prognostic biomarker
cancer immunity
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.02048/full

Similar Items

Similar Items